DOCSLIB.ORG

Advances in Systemic Therapy for HER2-Positive Metastatic Breast Cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Systemic Therapy for HER2-Positive Metastatic Breast Cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1 Available online http://breast-cancer-research.com/content/11/4/207 Review Advances in systemic therapy for HER2-positive metastatic breast cancer Phuong Khanh H Morrow1, Francisco Zambrana1,2 and Francisco J Esteva1 1Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Holcombe Boulevard, Houston, TX 77030, USA 2Current address: Department of Medical Oncology, Hospital Infanta Sofia, Paseo de Europa, 34, Madrid 28702, Spain Corresponding author: Phuong Khanh H Morrow, [email protected] Published: 15 July 2009 Breast Cancer Research 2009, 11:207 (doi:10.1186/bcr2324) This article is online at http://breast-cancer-research.com/content/11/4/207 © 2009 BioMed Central Ltd Abstract differentiation, survival, and migration that are associated with Human epidermal growth factor receptor (HER)2 over-expression HER2-positive breast cancers (Figure 1). Thus, women with is associated with a shortened disease-free interval and poor HER2-positive breast cancers exhibit significantly decreased survival. Although the addition of trastuzumab to chemotherapy in disease-free survival and overall survival (OS) [2-5]. the first-line setting has improved response rates, progression-free survival, and overall survival, response rates declined when trastu- This review discusses progress in the treatment of HER2- zumab was used beyond the first-line setting because of multiple positive metastatic breast cancer since the discovery of the mechanisms of resistance. Studies have demonstrated the clinical utility of continuing trastuzumab beyond progression, and further HER2 oncogene, with particular focus upon the mechanisms trials to explore this concept are ongoing. New tyrosine kinase of resistance to trastuzumab, treatment with trastuzumab inhibitors, monoclonal antibodies, PTEN (phosphatase and tensin beyond progression, use of lapatinib, and new biologic homolog) pathway regulators, HER2 antibody-drug conjugates, agents that may provide further therapeutic options in and inhibitors of heat shock protein-90 are being evaluated to patients with metastatic HER2-positive breast cancer. determine whether they may have a role to play in treating trastuzumab-resistant metastatic breast cancer. Use of trastuzumab in the treatment of metastatic breast cancer Introduction Trastuzumab is a humanized recombinant monoclonal anti- As knowledge about the treatment of breast cancer has grown, body, of the IgG1 type, which binds with high affinity to the attention has increasingly focused on developing a targeted extracellular domain of the HER2 receptor. The mechanism approach to this diverse disease. In particular, treatment of underlying trastuzumab’s efficacy in the treatment of HER2- human epidermal growth factor receptor (HER)2/neu-positive positive breast cancer is multifaceted and incompletely breast cancer has undergone significant advances since the understood. In vivo breast cancer models have demonstrated cloning of the HER2 oncogene in 1984 [1]. that trastuzumab induces antibody-dependent cellular cyto- toxicity through activation of Fc receptor expressing cells (for The HER2 oncogene encodes one of four transmembrane example, macrophages and natural killer cells), leading to receptors within the erbB family. Its over-expression, which lysis of tumor cells [6,7]. Trastuzumab has also been shown to occurs in approximately 25% of all breast cancer tumors, is downregulate p185ErbB2 [8]. In addition, trastuzumab blocks associated with a shortened disease-free interval and poor the release of the extracellular domain of HER2 by inhibiting survival [2]. Following ligand binding, the glycoprotein cleavage of the HER2 protein by ADAM (a disintegrin and receptor is activated through homodimerization or hetero- metalloproteinase domain) metalloproteinases [9]. Significant dimerization, leading to a cascade of events that involves declines in serum HER2 levels are a predictor of outcome activation of the tyrosine kinase domain, Ras/Raf/mitogen- after trastuzumab-based therapy [10-12]. Furthermore, trastu- activated protein kinase (MAPK) pathway, and phosphatidyl- zumab inhibits downstream PI3K-Akt signaling, leading to inositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin apoptosis [13]. It has also been shown that trastuzumab (mTOR). This sequence promotes the rapid cell growth, downregulates proteins that are involved in p27kip1 seques- 17-AAG = 17-(allylamino)-17-demethoxygeldanamycin; CR = complete response; EGFR = epidermal growth factor receptor; HER = human epi- dermal growth factor receptor; HR = hazard ratio; IGF-IR = insulin-like growth factor receptor-I; MAPK = mitogen-activated protein kinase; mTOR = mammalian target of rapamycin; OS = overall survival; PI3K = phosphatidylinositol-3-kinase; PR = partial response; PTEN = phosphatase and tensin homolog; TTP = time to progression; VEGF = vascular endothelial growth factor. Page 1 of 10 (page number not for citation purposes) Breast Cancer Research Vol 11 No 4 Morrow et al. Figure 1 The HER2 family and interrelated signaling and events. The binding of ligands, including epidermal growth factor and transforming growth factor-α, leads to the activation of signaling cascades involving Ras/Raf/MAPK, PI3K/Akt/mTOR, and JAK/STAT. This sequence of events promotes the apoptosis, proliferation, survival, migration, angiogenesis, and metastasis of HER2-over-expressing breast cancers. BTC, betacellulin; EGF, epidermal growth factor; EPG, epigen; EPR, epiregulin; HB-EGF, heparin-binding EGF-like growth factor; HER, human epidermal growth factor receptor; JAK, Janus kinase; JNK, c-Jun N-terminal kinase 1; mTOR, mammalian target of rapamycin; MAPK, mitogen-activated protein kinase; MEK, mitogen-induced extracellular kinase; MEKK, mitogen-activated protein/ERK kinase kinase; NRG, neuregulin; PI3K, phosphatidylinositol 3-kinase; STAT, signal transducer and activator of transcription; TGF, transforming growth factor; TK, tyrosine kinase. tration, causing release of p27kip1 and enabling inhibition of inositol-3,4,5 triphosphate, which is the site that recruits the cyclin E/Cdk2 complexes and subsequent G1 arrest [14]. pleckstrin-homology domain of Akt to the cell membrane Moreover, trastuzumab has been shown to exert antiangio- [24,25]. PTEN inhibits the ability of PI3K to catalyze the genic effects through normalization of microvessel density [15]. production of phosphotidylinositol-3,4,5 triphosphate and thus antagonizes the Akt cascade [26]. Loss of PTEN Although the mechanism that accounts for trastuzumab’s function occurs in approximately 50% of all breast cancers antitumor activity remains incompletely understood and [27]. Restoration of PTEN expression impedes Akt activation requires further elucidation, the results of the inclusion of and increases apoptosis [28]. Nagata and coworkers [24] trastuzumab in the treatment of HER2-positive breast cancer demonstrated that inhibition of PTEN expression by antisense are clear. Slamon and colleagues [16] found that addition of oligonucleotides resulted in trastuzumab resistance in vitro trastuzumab to chemotherapy, in the first-line setting, resulted and in vivo. Specifically, tumors in which PTEN expression in a significantly improved objective response, time to disease was abrogated by antisense oligonucleotides exhibited tumor progression, and OS. Combinations of trastuzumab with growth patterns that were unaffected by trastuzumab taxanes, platinum salts, vinorelbine, and capecitabine have administration. Patients with PTEN-deficient tumors demon- yielded benefits in the treatment of HER2-positive metastatic strated significantly lower complete response (CR) and breast cancer [17-23]. However, other trials demonstrated partial response (PR) rates to trastuzumab plus taxane that response rates declined markedly when trastuzumab was therapy than those who had PTEN-expressing tumors. used beyond the first-line setting, indicating the development of resistance to this agent. Independent of PTEN mutations, constitutive Akt phosphory- lation may also occur in HER2-over-expressing tumors [29]. Mechanisms of resistance to trastuzumab PTEN/PI3K/mTOR/Akt pathways MUC4 overexpression PTEN (phosphatase and tensin homolog) is a tumor sup- MUC4 is a membrane-associated, glycosylated mucin that pressor gene that causes dephosphorylation of phosphotidyl- has been shown to be over-expressed in breast cancer cells Page 2 of 10 (page number not for citation purposes) Available online http://breast-cancer-research.com/content/11/4/207 [30]. In rat models, MUC4 forms a complex with the HER2 implying that the increase in VEGF protein expression was protein and potentiates its phosphorylation, leading to cell mediated by post-transcriptional changes. In addition, when proliferation [30,31]. In addition to its ligand activity, MUC4 bevacizumab was added to a trastuzumab-based regimen for inhibits binding of trastuzumab to the HER2 receptor. mice bearing tumors of the 231-H2N cell line, a HER2-over- Utilizing JIMT-1, a HER2-over-expressing cell line with primary expressing variant of the MDA-MB-231 cell line, tumor resistance to trastuzumab, Nagy and colleagues [32] growth was delayed significantly. Their cumulative findings demonstrated that MUC4 expression was higher in this indicate that upregulation of VEGF may contribute to the trastuzumab-resistant cell line than in trastuzumab-sensitive mechanism of trastuzumab resistance, and dual inhibition of cell lines, and that the level of MUC4 expression inversely these pathways is currently
Load more

Recommended publications
  • Promoter Janus Kinase 3 Proximal Characterization and Analysis Of
    The Journal of Immunology Characterization and Analysis of the Proximal Janus Kinase 3 Promoter1 Martin Aringer,2*† Sigrun R. Hofmann,2* David M. Frucht,* Min Chen,* Michael Centola,* Akio Morinobu,* Roberta Visconti,* Daniel L. Kastner,* Josef S. Smolen,† and John J. O’Shea3* Janus kinase 3 (Jak3) is a nonreceptor tyrosine kinase essential for signaling via cytokine receptors that comprise the common ␥-chain (␥c), i.e., the receptors for IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. Jak3 is preferentially expressed in hemopoietic cells and is up-regulated upon cell differentiation and activation. Despite the importance of Jak3 in lymphoid development and immune function, the mechanisms that govern its expression have not been defined. To gain insight into this issue, we set out to characterize the Jak3 promoter. The 5؅-untranslated region of the Jak3 gene is interrupted by a 3515-bp intron. Upstream of this intron and the transcription initiation site, we identified an ϳ1-kb segment that exhibited lymphoid-specific promoter activity and was responsive to TCR signals. Truncation of this fragment revealed that core promoter activity resided in a 267-bp fragment that contains putative Sp-1, AP-1, Ets, Stat, and other binding sites. Mutation of the AP-1 sites significantly diminished, whereas mutation of the Ets sites abolished, the inducibility of the promoter construct. Chromatin immunoprecipitation assays showed that histone acetylation correlates with mRNA expression and that Ets-1/2 binds this region. Thus, transcription factors that bind these sites, especially Ets family members, are likely to be important regulators of Jak3 expression.
    [Show full text]
  • Targeted and Novel Therapy in Advanced Gastric Cancer Julie H
    Selim et al. Exp Hematol Oncol (2019) 8:25 https://doi.org/10.1186/s40164-019-0149-6 Experimental Hematology & Oncology REVIEW Open Access Targeted and novel therapy in advanced gastric cancer Julie H. Selim1 , Shagufta Shaheen2 , Wei‑Chun Sheu3 and Chung‑Tsen Hsueh4* Abstract The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of angiogenesis, human epidermal growth factor receptor 2 (HER2), mesenchymal–epithelial transition, epidermal growth factor receptor, mammalian target of rapamycin, claudin‑18.2, programmed death‑1 and DNA. Addition of trastuzumab to platinum‑ based chemotherapy has become standard of care as front‑line therapy in advanced GC overexpressing HER2. In the second‑line setting, ramucirumab with paclitaxel signifcantly improves overall survival compared to paclitaxel alone. For patients with refractory disease, apatinib, nivolumab, ramucirumab and TAS‑102 have demonstrated single‑agent activity with improved overall survival compared to placebo alone. Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability‑high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non‑inferior outcome in frst‑line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC. Keywords: Gastric cancer, Targeted therapy, Human epidermal growth factor receptor 2, Programmed death‑1, Vascular endothelial growth factor receptor 2 Background GC mortality which is consistent with overall decrease in Gastric cancer (GC), including adenocarcinoma of the GC-related deaths [4]. gastroesophageal junction (GEJ) and stomach, is the ffth Tere have been several eforts to perform large-scale most common cancer and the third leading cause of can- molecular profling and classifcation of GC.
    [Show full text]
  • Biomarker Testing in Non- Small Cell Lung Cancer (NSCLC)
    The biopharma business of Merck KGaA, Darmstadt, Germany operates as EMD Serono in the U.S. and Canada. Biomarker testing in non- small cell lung cancer (NSCLC) Copyright © 2020 EMD Serono, Inc. All rights reserved. US/TEP/1119/0018(1) Lung cancer in the US: Incidence, mortality, and survival Lung cancer is the second most common cancer diagnosed annually and the leading cause of mortality in the US.2 228,820 20.5% 57% Estimated newly 5-year Advanced or 1 survival rate1 metastatic at diagnosed cases in 2020 diagnosis1 5.8% 5-year relative 80-85% 2 135,720 survival with NSCLC distant disease1 Estimated deaths in 20201 2 NSCLC, non-small cell lung cancer; US, United States. 1. National Institutes of Health (NIH), National Cancer Institute. Cancer Stat Facts: Lung and Bronchus Cancer website. www.seer.cancer.gov/statfacts/html/lungb.html. Accessed May 20, 2020. 2. American Cancer Society. What is Lung Cancer? website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Accessed May 20, 2020. NSCLC is both histologically and genetically diverse 1-3 NSCLC distribution by histology Prevalence of genetic alterations in NSCLC4 PTEN 10% DDR2 3% OTHER 25% PIK3CA 12% LARGE CELL CARCINOMA 10% FGFR1 20% SQUAMOUS CELL CARCINOMA 25% Oncogenic drivers in adenocarcinoma Other or ADENOCARCINOMA HER2 1.9% 40% KRAS 25.5% wild type RET 0.7% 55% NTRK1 1.7% ROS1 1.7% Oncogenic drivers in 0% 20% 40% 60% RIT1 2.2% squamous cell carcinoma Adenocarcinoma DDR2 2.9% Squamous cell carcinoma NRG1 3.2% Large cell carcinoma
    [Show full text]
  • Kinase Inhibitors: an Introduction
    David Peters Baran Group Meeting Kinase Inhibitors: An Introduction 2/2/19 INTRODUCTION SIGNAL TRANSDUCTION KINASES ARE IMPORTANT IN HUMAN BIOLOGY/DISEASE: The process describing how a signal (chemical/physical) is transmitted through a - Kinases are a superfamily of proteins (5th largest in humans) cell ultimately resulting in a cellular response - 518 genes and 106 pseudogenes - Diverse in size, subunit structure, and cellular location RECEPTOR TRANSDUCERS EFFECTORS - ~260 residues make up their conserved catalytic core - dysregulation of kinases occurs in many diseases (cancer, inflamatory, degenerative, and autoimmune diseases) - signals can originate inside or outside the cell - 244 of the 518 map to disease loci - signals generally passed through a series of steps (signal transduction pathway) often consisting of multiple enzymes and messengers protein O - pathways open possibility for signal aplification (>1x106) kinase ATP + PROTEIN OH ADP + PROTEIN O P O - Extracellular signals transduced by RTKs, GPCR’s, guanlyl cyclases, or ligand-gated Ion channels O - Phosphorylation is the most prominent covalent modification/signal in KINASES INHIBITORS ARE IMPORTANT IN DISEASE THERAPY/RESEARCH: cellular regulation - currently 51 FDA approved small molecule kinase inhibitors - “converter enzymes” (protein kinases and phosphoprotein phosphorlyases) - 4 FDA approved antibody kinase inhibitors are regulated; conserve ATP/maintain desired target protein state - thousands of known inhibitors spanning the kinome - pathway ends by affecting biomolecule
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Role of Signaling Pathways in the Development and Treatment of Hepatocellular Carcinoma
    Oncogene (2010) 29, 4989–5005 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 www.nature.com/onc REVIEW The role of signaling pathways in the development and treatment of hepatocellular carcinoma S Whittaker1,2, R Marais3 and AX Zhu4 1Dana-Farber Cancer Institute, Boston, MA, USA; 2The Broad Institute, Cambridge, MA, USA; 3Institute of Cancer Research, London, UK and 4Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA Hepatocellular carcinoma (HCC) is a highly prevalent, malignancy in adults (Pons-Renedo and Llovet, 2003). treatment-resistant malignancy with a multifaceted mole- For the vast majority of patients, HCC is a late cular pathogenesis. Current evidence indicates that during complication of chronic liver disease, and as such, is hepatocarcinogenesis, two main pathogenic mechanisms often associated with cirrhosis. The main risk factors for prevail: (1) cirrhosis associated with hepatic regeneration the development of HCC include infection with hepatitis after tissue damage caused by hepatitis infection, toxins B virus (HBV) or hepatitis C virus (HCV). Hepatitis (for example, alcohol or aflatoxin) or metabolic influ- infection is believed to be the main etiologic factor in ences, and (2) mutations occurring in single or multiple 480% of cases (Anzola, 2004). Other risk factors oncogenes or tumor suppressor genes. Both mechanisms include excessive alcohol consumption, nonalcoholic have been linked with alterations in several important steatohepatitis, autoimmune hepatitis, primary biliary cellular signaling pathways. These pathways are of cirrhosis, exposure to environmental carcinogens (parti- interest from a therapeutic perspective, because targeting cularly aflatoxin B) and the presence of various genetic them may help to reverse, delay or prevent tumorigenesis.
    [Show full text]
  • One Target, Different Effects: a Comparison of Distinct Therapeutic Antibodies Against the Same Targets
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 43, No. 10, 539-549, October 2011 One target, different effects: a comparison of distinct therapeutic antibodies against the same targets Hyunbo Shim ple, four antibodies against TNF-α have been approved by the FDA -- infliximab, adalimumab, golimumab, and Department of Life Science certolizumab pegol -- with many more in clinical and Division of Life and Pharmaceutical Sciences preclinical development. The situation is similar for Ewha Womans University HER2, CD20, EGFR, and VEGF, each having one or Seoul 120-750, Korea more approved antibodies and many more under Correspondence: Tel, 82-2-3277-4240; development. This review discusses the different bind- Fax, 82-2-3277-3760; E-mail, [email protected] ing characteristics, mechanisms of action, and bio- http://dx.doi.org/10.3858/emm.2011.43.10.063 logical and clinical activities of multiple monoclonal antibodies against TNF-α, HER-2, CD20, and EGFR and Accepted 2 August 2011 provides insights into the development of therapeutic Available Online 3 August 2011 antibodies. Abbreviations: ADC, antibody-drug conjugate; ADCC, antibody- dependent cellular cytotoxicity; CD20, cluster of differentiation Keywords: antibodies, monoclonal; antigens, CD20; 20; CDC, complement dependent cytotoxicity; CLL, chronic pharmacology; receptor, epidermal growth factor; re- lymphocytic leukemia; ECD, extracellular domain; EGFR, epi- ceptor, erbB-2; tumor necrosis factor-α dermal growth factor receptor; EpCAM, epithelial cell adhe- sion molecule; FcγR, Fc gamma receptor;
    [Show full text]
  • Epigenetic Gene Regulation by Janus Kinase 1 in Diffuse Large B-Cell Lymphoma
    Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma Lixin Ruia,b,c,1,2, Amanda C. Drennanb,c,1, Michele Ceribellia,1, Fen Zhub,c, George W. Wrightd, Da Wei Huanga, Wenming Xiaoe, Yangguang Lib,c, Kreg M. Grindleb,c,LiLub,c, Daniel J. Hodsona, Arthur L. Shaffera, Hong Zhaoa, Weihong Xua, Yandan Yanga, and Louis M. Staudta,2 aLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892; bDepartment of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705; cCarbone Cancer Center, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705; dBiometric Research Branch, DCTD, National Cancer Institute, NIH, Bethesda, MD 20892; and eDivision of Bioinformatics and Biostatistics, National Center for Toxicological Research/Food and Drug Administration, Jefferson, AR 72079 Contributed by Louis M. Staudt, September 29, 2016 (sent for review July 22, 2016; reviewed by Anthony R. Green and Ross L. Levine) Janus kinases (JAKs) classically signal by activating STAT transcription promote STAT dimerization, nuclear translocation, and binding factors but can also regulate gene expression by epigenetically to cis-regulatory elements to regulate transcription (15, 17). This phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large canonical JAK/STAT pathway is deregulated in several hemato- B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated logic malignancies (16). In DLBCL, STAT3 is activated in the B-cell (ABC) subtype and is triggered by autocrine production of IL-6 ABC subtype and regulates gene expression to promote the sur- and IL-10.
    [Show full text]
  • Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics
    Oncogene (2007) 26, 6577–6592 & 2007 Nature Publishing Group All rights reserved 0950-9232/07 $30.00 www.nature.com/onc REVIEW Targeting the function of the HER2 oncogene in human cancer therapeutics MM Moasser Department of Medicine, Comprehensive Cancer Center, University of California, San Francisco, CA, USA The year 2007 marks exactly two decades since human HER3 (erbB3) and HER4 (erbB4). The importance of epidermal growth factor receptor-2 (HER2) was func- HER2 in cancer was realized in the early 1980s when a tionally implicated in the pathogenesis of human breast mutationally activated form of its rodent homolog neu cancer (Slamon et al., 1987). This finding established the was identified in a search for oncogenes in a carcinogen- HER2 oncogene hypothesis for the development of some induced rat tumorigenesis model(Shih et al., 1981). Its human cancers. An abundance of experimental evidence human homologue, HER2 was simultaneously cloned compiled over the past two decades now solidly supports and found to be amplified in a breast cancer cell line the HER2 oncogene hypothesis. A direct consequence (King et al., 1985). The relevance of HER2 to human of this hypothesis was the promise that inhibitors of cancer was established when it was discovered that oncogenic HER2 would be highly effective treatments for approximately 25–30% of breast cancers have amplifi- HER2-driven cancers. This treatment hypothesis has led cation and overexpression of HER2 and these cancers to the development and widespread use of anti-HER2 have worse biologic behavior and prognosis (Slamon antibodies (trastuzumab) in clinical management resulting et al., 1989).
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • JAK3 Deficiency, (SCID T-B+)
    JAK3 deficiency, (SCID T-B+) Author: Professor Luigi D. Notarangelo1,2 Creation Date: November 2001 Update: January 2005 1member of the European editorial committee of Orphanet encyclopedia 2Department of Pediatrics, University of Brescia, Spedali Civil, 25123 Brescia, Italy. [email protected] Abstract Keywords Diagnosis criteria/definition Differential diagnosis Prevalence Clinical description Treatment Etiology Diagnostic methods Genetic counseling Antenatal diagnosis Unresolved questions References Abstract JAK3 (Janus Kinase 3) deficiency is an autosomal recessive form of severe combined immune deficiency (SCID). It is characterized by lack of circulating T and NK (Natural Killer) cells and normal number of B lymphocytes. The disease is due to mutations in the JAK3 gene encoding an intracellular tyrosine kinase that is physically and functionally coupled with several cytokine receptors. Identification of gene anomalies has allowed physicians to make the diagnosis (even prenatal), and may prompt novel forms of treatment based on gene therapy. Although a relatively low number of JAK3-deficient subjects have been diagnosed, JAK3 deficiency represents an important cause of autosomal recessive SCID in the United States and its prevalence in Europe appears to be even higher. However it is considered as a rare disease (incidence is between 1/100,000 and 1/1,000,000 live births). JAK3-deficient patients present with the classical clinical features of SCID in the first few months of life, i.e. chronic diarrhea, failure to thrive, recurrent respiratory infection and/or generalized infections from opportunistic pathogens, or signs of graft-versus-host reaction (skin rash, abnormalities of liver function, pancytopenia) from transplacental acquired maternal T cells.
    [Show full text]